Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
Specialised Therapeutics (ST) expanded its partnership with Incyte (NASDAQ: INCY) to commercialize, distribute, and register ruxolitinib cream (Opzelura®) in Australia. ST will handle regulatory, marketing, and distribution, while Incyte retains development and manufacturing. Opzelura is approved for treating vitiligo and atopic dermatitis in the U.S. and EU. ST aims to navigate regulatory pathways for Australian approval.






